Entero Therapeutics Inc.

4.4600+0.51 (+12.9%)

Oct 29, 4:00:02 PM EDT · NasdaqCM · ENTO · USD

Upcoming Earnings

Report date

Key Stats

Market Cap

9.47M

P/E (TTM)

Basic EPS (TTM)

-11.97

Dividend Yield

Recent Filings

8-K

Entero raises $500K via notes and warrants

10/22/25Oct 22, 2025

Entero Therapeutics secured $500,000 in initial funding on October 17, 2025, via a private placement of a non-interest-bearing promissory note maturing in one year and one day, paired with warrants for 200,000 common shares at $2.50 each, exercisable post-stockholder approval. The deal allows up to $5 million total through subsequent closings, with proceeds earmarked for general corporate needs like working capital or acquisitions. Warrants expire five years after approval, but hinge on Nasdaq-compliant stockholder votes every 90 days if needed. This non-dilutive cash bolsters liquidity amid biotech pressures.

8-K

Entero acquires GridAI for AI grid tech

10/6/25Oct 6, 2025

Entero Therapeutics closed a share exchange on September 30, 2025, acquiring 100% of GridAI Corp, which owns 75% of AMPX UK Holdings, for 424,348 common shares and 38,801,546 Series H preferred shares convertible into 38,801,546 common shares post-shareholder approval, granting sellers 82.5% ownership on a fully diluted basis. This positions Entero in the booming AI energy infrastructure market, leveraging GridAI's platform to manage grid-edge demand amid surging data center power needs. Sellers gain board seats and registration rights. Nasdaq compliance hinges on approval.

8-K

Interim CEO consulting deal

9/12/25Sep 12, 2025

Entero Therapeutics formalized Jason D. Sawyer's role as interim CEO through a consulting agreement with Access Alternative Group S.A., effective September 4, 2025, at $12,500 monthly compensation. Sawyer will manage operations and craft strategy remotely, backed by full DGCL indemnification. This setup stabilizes leadership amid transitions. Yet, the month-to-month term signals flexibility.

8-K

Entero swaps interim CEO

9/9/25Sep 9, 2025

Entero Therapeutics abruptly terminated Richard Joel Paolone as interim CEO and board chairman on September 3, 2025, without cause, ending his consulting agreement with immediate payment in lieu of notice. The board swiftly appointed Jason D. Sawyer, a 32-year alternative investment veteran with biotech board experience, as new interim CEO the next day. No disagreements over company practices surfaced. This leadership pivot signals fresh strategic direction amid ongoing operations.

8-K

1-for-3 reverse split announced

8/15/25Aug 15, 2025

Entero Therapeutics approved a 1-for-3 reverse stock split, effective August 18, 2025, to boost its share price above $1.00 and regain Nasdaq compliance under Listing Rule 5550(a)(2). This slashes outstanding shares from 4.77 million to 1.59 million, with cash for fractional shares. Compliance hinges on 10 consecutive days above $1.00. Yet success isn't assured.

About

Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. It develops Adrulipase, an oral, non-systemic, and biologic capsule that is in Phase 2 clinical trials for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis (CF) and chronic pancreatitis (CP), as well as a recombinant lipase enzyme that enables the digestion of fats and other nutrients in CF and CP patients with EPI. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

CEO

Mr. Jason David Sawyer

IPO

10/11/2016

Website

https://www.enterothera.com

Employees

Sector

Healthcare

Industry

Biotechnology